Stoke: 'Buy' Zorevunersen NDA SCN1A DS And STK-002 Advancement (NASDAQ:STOK)
· seekingalpha.com
Stoke Therapeutics stays a Buy as zorevunersen hits key Dravet milestones and STK-002 advances; strong cash runway to 2028. Click for more on STOK stock.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...